53 results about "Ototoxicity" patented technology

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, preferably of spiral ganglion neurons, by administration of a therapeutically effective amount of one or more molecules having erythropoietin activity selected from EPO, or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of EPO; a small molecule mimetic of EPO and an erythropoiesis stimulating agent. Also provided are improved compositions and methods for treatments of ototoxicity requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a molecule having erythropoietin activity.

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox-active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

The present invention relates to pharmaceutical compositions useful for topical, non-invasive delivery of an oligonucleotide to the ear and to methods for the treatment of an ear disorder, including hearing loss arising from chemical-induced ototoxicity, acoustic trauma and presbycusis; and microbial infections. The method comprises topically administering to the ear of a subject in need thereof a pharmaceutical composition comprising an inhibitory oligonucleotide, a permeability enhancer and a pharmaceutically acceptable carrier, wherein the oligonucleotide reduces or inhibits expression of a gene associated with the ear disorder in the subject.

A method of limiting noise damage to an individual includes receiving, by an ototoxicity application stored in a non-transitory memory and executed on a processor, a first individual exposure level toa first ototoxic condition in an area, correlating the first individual exposure level to an ototoxic effect, determining a noise level threshold based on the correlating, receiving a noise level exposure in the area, comparing the noise level threshold with the noise level exposure, and sending an alert when the noise level exposure exceeds the noise level threshold. The noise level threshold isbelow a standard noise level threshold.

The present invention provides methods of identifying compounds that protect against ototoxicity induced by one or more noxious stimuli, and methods of treating an individual with compounds identified using the present screening methods. Also provided are compounds demonstrated to have otoprotective effects.

The present invention relates to the use of a compound for the preparation of a medicament for the prevention and / or treatment of induced cytotoxicity, such as nephrotoxicity and ototoxicity, in particular said cytotoxicity is induced as a result of drug treatment. In a preferred embodiment, the compound has at least two nitrogen atoms, more preferably at least two amino groups. The compound of the present invention can block the binding of cytotoxic compounds to megalin receptors, thereby inhibiting the uptake of the cytotoxic compounds into cells. The present invention also relates to novel compounds for use in said treatment, as well as methods of reducing the cytotoxicity of cytotoxic compounds, more particularly gentamicin.

The present invention relates to use of DHA analogs and their pharmaceutical compositions for treating ototoxicity, by administering these compounds or pharmaceutical compositions to subjects in need thereof. Ototoxicity is defined as damage to the structures of the ear, such as the cochlea and vestibular system, by drugs or toxins. Ototoxicity can result in irreversible hearing loss, tinnitus, dysequilibrium, Meniere's disease, or vertigo.

The present invention relates to the use of neurotrophins in the treatment of hearing disorders related to hearing loss using the transtympanic route of administration, in particular in the treatment of sudden deafness, blast-induced hearing loss, ototoxicity, ARHL (age related hearing loss) and noise damage. The invention further relates to the use of compositions containing neurotrophins, in particular NGF, in the treatment of hearing disorders.

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

The present invention relates to the use of compounds for the manufacture of a medicament for the prophylaxis and / or treatment of induced cell toxicity, such as nephewrotoxicity and ototoxicity, in particular where the cell toxicity is induced by a medical treatment. In a preferred embodiment, the compounds have at least two nitrogen atoms, more preferably at least two amino groups. The compounds according to the invention are capable of docking binding of cell toxic compounds to the megalin receptor, and thereby inhibiting uptake of the cell toxic compounds into cells. The invention further relates to novel compounds for use in said treatment, as well as a method for reducing the cell toxicity of cell toxic compounds.

Loss of bilateral vestibular function is a chronic disease that may result from ototoxic, infectious, traumatic, autoimmune, or congenital causes. The purpose of the present invention is to improve the effectiveness of a vibrotactile feedback device. The present invention provides a vibrotactile feedback device for arrangement to a human body, comprising: a sensor arranged to sense a current posture of the human body relative to an environment; a haptic actuator arranged to allow the human body to perceive a posture deviation; an elongate carrier for holding the haptic actuator and the sensor in haptic communication with the human body and for holding the haptic actuator and the sensor substantially fixed relative to the human body; and a processing unit configured to: receive the current pose from the sensor; determining the posture deviation based on comparing the desired posture of the human body with the current posture; and transmitting an actuation signal to one or more of the haptic actuators based on the attitude deviation; wherein the haptic actuator is arranged to the carrier such that the haptic actuator is substantially arranged in a reference plane when the carrier is used; wherein the reference surface is functionally perpendicular to a central axis of a torso of the human body, and the reference surface intersects the torso to define a circumference to which the haptic actuators are arranged; and wherein the carrier comprises a stretchable material such that the relative distance between the haptic actuators and / or between the haptic actuators and the sensor is maintained irrespective of the length of the circumference.

Provided herein are methods for preventing and / or reducing the severity of drug induced ototoxicity. Provided herein are methods for recovery from hearing loss due to drug-induced ototoxicity.

Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described.

A method of treating inner ear hardness of hearing and restoring hearing of humans and animals after damage and loss of sensory hair cells in an organ of Corti based on regeneration biology includes administering a therapeutically effective amount of a compound including aminoalkyloxazole and aminoalkylthiazole carboxylic acid amides, or a pharmaceutically acceptable salt, a stereoisomer, a stereoisomer mixture, a tautomer or a prodrug compound thereof, directly or indirectly to damaged tissue structures in a cochlea, optionally, by transtympanal injection into a middle ear, by application to a round or oval window of an inner ear or by injection into the inner ear.